# Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

> **NCT00939523** · PHASE2 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Pituitary Adenomas
- Prolactinomas

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT00939523
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939523, "Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00939523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*